Extending postgrafting cyclosporine decreases the risk of severe graft-versus-host disease after nonmyeloablative hematopoietic cell transplantation.

Publication Type:

Journal Article

Source:

Transplantation, Volume 81, Issue 6, p.818-25 (2006)

Keywords:

Adolescent, Adult, Aged, Cyclosporine, Drug Administration Schedule, Female, Graft vs Host Disease, Hematologic Neoplasms, hematopoietic stem cell transplantation, Humans, Immunosuppressive Agents, Male, Middle Aged, RECURRENCE, Retrospective Studies, Time Factors

Abstract:

It is unknown whether the duration of systemic immunosuppressive treatment after allogeneic nonmyeloablative hematopoietic cell transplantation (HCT) might influence the incidence, severity, timing, and/or corticosteroid-responsiveness of graft-versus-host disease (GVHD).